Insulin lispro (ultra rapid formulation) - Eli lilly

Drug Profile

Insulin lispro (ultra rapid formulation) - Eli lilly

Alternative Names: LY-900014

Latest Information Update: 13 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Phase I Diabetes mellitus

Most Recent Events

  • 14 Nov 2017 Eli Lilly plans a phase I trial for Type-2 Diabetes Mellitus in Germany in November 2017 (NCT03341312)
  • 14 Nov 2017 Eli Lilly plans a phase I trial for Type 1 Diabetes Mellitus in Germany in November 2017 (NCT03341299)
  • 13 Nov 2017 Eli Lilly initiates enrolment in a phase I trial for Type 1 Diabetes Mellitus in Germany (SC) (NCT03341299)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top